Suche starten De menü de ClientConnect
Suche starten
Ergebnisse
Top-5-Suchergebnisse Alle Ergebnisse anzeigen Erweiterte Suche
Häufigste Suchbegriffe
Meistbesuchte Seiten
    Referenz: 20220828
    Veröffentlichungsdatum: 20 November 2023

    Projektträger – zwischengeschaltetes Finanzinstitut

    SAFEHEAL SAS

    Ort

    Beschreibung

    The project consists in a quasi-equity investment in Safeheal, a medical technology company based in France aiming to bring to market a solution to make colorectal cancer surgery more efficient and safer for patients.

    Additionality and Impact

    The Operation contributes to the InvestEU objective of research, development and innovation. The purpose of the loan is to provide direct, equity-type financing under EIB's Venture Debt Instrument to support research, development and innovation activities of the innovative company 'SafeHeal', a medical technology company based in France. The financing of this project addresses the failure in financial markets for RDI, arising from limited access to commensurate financing as a result of factors such as information asymmetries, misalignment of incentives, etc. The Company focuses on the development of innovative solutions to improve colorectal cancer surgeries by making them less intrusive to patients. By creating knowledge externalities, the project is expected to provide significant socio-economic benefits, will strengthen France and Europe's position in the field of advanced therapies, and it will help to create and retain skilled staff engaged in the Company's RDI activities. Thanks to the support of InvestEU, the EIB may provide long term financing in the form of venture debt to a highly innovative but high-risk early-stage company with no access to commercial debt. By contributing to extending the cash runway and therefore to de-risking the development plan of the company, the innovative EIB financing is expected to crowd-in third party investors (such as Venture Capitals, Strategic Investors, Private Equity players, etc.) and allow the company to accelerate its development and forming strategic alliances. The project would not have been carried out (to the same extent) by the EIB without the InvestEU support.

    Ziele

    The investment will finance the company's research, development and innovation (RDI) expenses as well as regulatory activities.

    Sektor(en)

    • Industrie - Verarbeitendes Gewerbe/Herstellung von Waren

    Vorgeschlagene EIB-Finanzierung (voraussichtlicher Betrag)

    EUR 15 million

    Gesamtkosten (voraussichtlicher Betrag)

    EUR 44 million

    Umweltaspekte

    The promoter's investments concern RDI activities that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under Directive 2011/92/EU. Full environmental details will be verified during appraisal.

    Auftragsvergabe

    The Promoter is a private company, not operating in the utilities sector and does not have the status of a contracting authority; thus the project is not covered by the EU directives on procurement. However, the Promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank's services will verify details during the project due diligence.

    Projektstatus

    Unterzeichnet - 29/09/2023

    Milestone
    In Prüfung
    Genehmigt
    Unterzeichnet
    19 Juli 2023
    29 September 2023

    Haftungsausschluss

    Bis Finanzierungen vom Verwaltungsrat genehmigt und anschließend unterzeichnet werden, befinden sich die Projekte in der Prüfungs- oder Verhandlungsphase. Die Angaben auf dieser Seite sind daher unverbindlich.
    Sie dienen lediglich der Transparenz und stellen nicht die offizielle EIB-Politik dar (vgl. auch die erklärenden Anmerkungen).

    Tags

    Frankreich Industrie